Cancer prevention trials and primary care physicians: Factors associated with recommending trial enrollment

2002, Chemoprevention of breast cancer: recommendations and rationale. U.S. Preventive Services Task Force, Ann Intern Med, 137, 56, 10.7326/0003-4819-137-1-200207020-00016 Benson, 1991, Oncologists’ reluctance to accrue patients onto clinical trials: an Illinois Cancer Center study, J Clin Oncol, 9, 2067, 10.1200/JCO.1991.9.11.2067 Winn, 1994, Obstacles to the accrual of patients in clinical trials in the community setting, Semin Oncol, 21, 112 Mansour, 1994, Barriers to clinical trials. Part III: knowledge and attitudes of health care providers, Cancer, 74, 2672, 10.1002/1097-0142(19941101)74:9+<2672::AID-CNCR2820741815>3.0.CO;2-X Lerman, 1994, Recruiting high risk women into a breast cancer health promotion trial, Cancer Epidemiol Biomark Prev, 3, 271 Kinney, 1998, The effect of physician recommendation on enrollment in the breast cancer chemoprevention trial, Prev Med, 27, 713, 10.1006/pmed.1998.0349 Frayne, 2001, Attitudes of primary care physicians toward cancer-prevention trials: a focus group analysis, J Natl Med Assoc, 93, 450 Nattinger, 1992, Geographic variation in the use of breast-conserving treatment for breast cancer, New Eng J Med, 326, 1102, 10.1056/NEJM199204233261702 Farrow, 1992, Geographic variation in the treatment of localized breast cancer, New Eng J Med, 326, 1097, 10.1056/NEJM199204233261701 Cochran, 1957 Fisher, 1998, Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study, J Natl Cancer Inst, 90, 1371, 10.1093/jnci/90.18.1371 Vogel, 2002, The study of tamoxifen and raloxifene: preliminary enrollment data from a randomized breast cancer risk reduction trial, Clin Breast Cancer, 3, 153, 10.3816/CBC.2002.n.020 Taylor, 2005, Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump, Ann Fam Med, 3, 242, 10.1370/afm.284 Yee, 2003, Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier?, J Clin Oncol, 21, 1618, 10.1200/JCO.2003.12.044 Hutchins, 1999, Underrepresentation of patients 65 years of age or older in cancer-treatment trials, New Eng J Med, 341, 2061, 10.1056/NEJM199912303412706 National Surgical Adjuvant Breast and Bowel Project: P-1 Protocol. Section 6.0 subject eligibility and ineligibility, September 1994. Nattinger, 1992, Geographic variation in the use of breast-conserving treatment for breast cancer, New Eng J Med, 326, 1102, 10.1056/NEJM199204233261702 Farrow, 1992, Geographic variation in the treatment of localized breast cancer, New Eng J Med, 326, 1097, 10.1056/NEJM199204233261701 Emanuel, 1995, Preserving the physician–patient relationship in the era of managed care, JAMA, 273, 323, 10.1001/jama.1995.03520280069043 Glass, 1996, The impact of managed care on patients’ trust in medical care and their physicians, JAMA, 275, 1693, 10.1001/jama.1996.03530450083048 Asch, 1997, Response rate to mail surveys published in medical journals, J Clin Epidemiol, 50, 1129, 10.1016/S0895-4356(97)00126-1 Marwell, 1996, Patient factors associated with breast cancer screening among older women, J Am Geriatr Soc, 44, 1210, 10.1111/j.1532-5415.1996.tb01371.x